Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oral drug could slow MS progression in major trial

NCT ID NCT07067463

Recruiting now Disease control Sponsor: Zenas BioPharma (USA), LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether the oral drug orelabrutinib can slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 705 adults aged 18–60 with PPMS will receive either orelabrutinib or a placebo for up to 5 years. The study measures time to worsening disability using walking, hand function, and standard disability scales.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Orelabrutinib (a BTK inhibitor taken as a pill)

What this could lead to

If successful, this could provide a new oral treatment option to slow disability progression in people with primary progressive multiple sclerosis.

What could go wrong

This is a large phase 3 trial, but the drug may not prove effective or could have side effects. The study lasts up to 5 years, and results are not guaranteed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) PRIMARY PROGRESSIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis primary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS (MS) PRIMARY PROGRESSIVE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arizona Neuroscience Research, LLC

    RECRUITING

    Pheonix, Arizona, 85032, United States

  • Lone Star Neurology

    RECRUITING

    San Antonio, Texas, 78258, United States

  • NEUROHK, s.r.o.

    RECRUITING

    Choceň, 56501, Czechia

  • NZOZ Neuromed M. i M. Nastaj Sp.P

    RECRUITING

    Lublin, 20-064, Poland

  • NZOZ Novo Med

    RECRUITING

    Katowice, Silesian Voivodeship, 40-584, Poland

  • Neuro Centrum Science Gmbh Albert-Schwitzer

    RECRUITING

    Erbach im Odenwald, Hesse, 64711, Germany

  • Neurology Associates, PA

    RECRUITING

    Maitland, Florida, 32751, United States

  • Neurology Clinic, P.C.

    RECRUITING

    Cordova, Tennessee, 38018, United States

  • Nova Clinical Research, LLC

    RECRUITING

    Bradenton, Florida, 34209, United States

  • Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy

    RECRUITING

    Poznan, Wielkopolska, 61-853, Poland

  • Perseverance Research Center

    RECRUITING

    Scottsdale, Arizona, 85253, United States

  • Premier Neurology

    RECRUITING

    Greenville, South Carolina, 29605, United States

  • Regina Berkovich MD, PhD Inc.

    RECRUITING

    West Hollywood, California, 90048, United States

  • Texas Institute for Neurological Disorders

    RECRUITING

    Sherman, Texas, 75092, United States

  • The Boster Center for Multiple Sclerosis

    RECRUITING

    Columbus, Ohio, 43235, United States

  • Velocity Clinical Research, Raleigh Neurology

    RECRUITING

    Raleigh, North Carolina, 27607, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States